Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Therapeutic Drug Monitoring|November 16, 2013
Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotypeMagnhild Hendset, Espen Molden, Magnus Knape, et al.Journal of Clinical Psychopharmacology|November 14, 2009
Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidoneMagnhild Hendset, Espen Molden, Helge Refsum, et al.Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|March 19, 2005
[Dietary supplements--surprise pills?]Magnhild Hendset, Niclas Lunder, Helge Refsum, et al.European Journal of Clinical Pharmacology|September 11, 2007
Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazoleMagnhild Hendset, Monica Hermann, Hilde Lunde, et al.Therapeutic Drug Monitoring|November 12, 2010
The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring dataMagnhild Hendset, Espen Molden, Torill Bakko Enoksen, et al.Therapeutic Drug Monitoring|January 19, 2006
Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram)Ida Rudberg, Magnhild Hendset, Linda Hårstad Uthus, et al.Pageof 1